Ceragon (NASDAQ: CRNT), a leading solutions provider of end-to-end wireless connectivity, announces that management will participate in the following investor conferences in November: Event:...

- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming...

-Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a...